SENTARA

RECEIVED
REGION I

'05 MAR 11 P2:04

Sentara Williamsburg Community Hospital
301 Monticello Avenue
Williamsburg Va. 23185
www.sentara.com

March 4, 2005

U.S. Nuclear Regulatory Commission
LAT – Division of Nuclear Materials Safety, Region I
475 Allendale Road
King of Prussia, PA 19406

FAX: (610) 337-5269

RE: Amendment Materials License 45-16209-02 03014703

Sentara Williamsburg Community Hospital would like to amend its Materials License to add the following individuals. The Radiation Safety Committee met in executive session on November 18, 2004 to review the credentials of the individuals listed below. All were approved based on the fact that they are either named on another NRC license or have certification by the American Board of Radiology (see attached documentation).

Authorized User	Materials & Use	License No.
Michael S. Montileone, MD	Medical uses identified in 35.100; 35.200	45-09087-01
Kendall L. Capecci, MD	Medical uses identified in 35.100; 35.200	45-00317-02
Andrew D. Lauve, MD	Medical uses identified in 35.400; 35.600	

If you have any questions regarding this notification or the attached materials, please contact me at (757) 259-6011.

Sincerely,

Robert Graves, FACHE
Vice President and Administrator

Enclosures

cc: Ms. Maureen Green
Ms. Elizabeth Davis

136673

NMSS/RGNI MATERIALS-002

February 21, 2005

U.S. Nuclear Regulatory Commission
LAT - Division of Nuclear Materials Safety, Region I
475 Allendale Road
King of Prussia, PA 19406

FAX (610) 337-5269

RE: Amendment Materials License 45-16209-02

Sentara Williamsburg Community Hospital would like to amend its Materials License to add the following individuals. The Radiation Safety Committee met in executive session on November 18, 2004 to review the credentials of the individuals listed below. All were approved based on the fact they are either named on another NRC license or have certification by the American Board of Radiology (See attached documentation).

Authorized User	Materials & Use	License No.
Michael S. Montileone, M.D.	Medical uses identified in 35.100; 35.200	45-09087-01
Kendall L. Capecci, M.D.	Medical uses identified in 35.100; 35.200	45-00317-02
Andrew D. Lauve, M.D.	Medical uses identified in 35.400; 35.600	

If you have any question regarding this notification letter or the attached materials, please contact me at 757-259-6011.

Sincerely,

[redacted]

Michael S. Montileone, M.D

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 37

Duplicate ▪ Duplicate ▪ Duplicate

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the application dated March 31, 2004,
1. Sentara CarePlex Hospital	3. License No. 45-09087-01 is renewed in its entirety to read as follows:
2. 3000 Coliseum Drive Hampton, Virginia 23666	4. Expiration Date: September 30, 2014
	5. Docket No. 030-03331

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any (iodine 131 in capsule form only)	C. As needed [not to exceed 10 curies (Ci) of iodine 131]
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed source (Bard Brachytherapy Model STM-1251)	D. 1 Ci
E. Any byproduct material permitted by 10 CFR 31.11	E. Prepackaged Kits	E. As needed
F. Gadolinium 153	F. Sealed source (Isotope Products Laboratories, Inc. Model No. 301B; Du Pont Merck Pharmaceutical Co. Model No. NES-8424)	F. 1 Ci total; no single source to exceed 323 millicuries

Duplicate ▪ Duplicate ▪ Duplicate

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No.
45-09087-01

Docket No.
030-03331

Amendment No.
37

9. Authorized use:

   A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
   B. Any imaging and localization study permitted by 10 CFR 35.200.
   C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
   D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
   E. *In vitro* studies.
   F. For possession and use in SMV America Model No. PS96 transmission attenuation correction unit. Possession in a shielded shipping cask.

CONDITIONS

10. Licensed material may be used or possessed only at the licensee's facilities located at Sentara CarePlex Hospital, 3000 Coliseum Drive, Hampton, Virginia, and Sentara Cancer Institute - Peninsula, 3000 Coliseum Drive, Suite 100, Hampton, Virginia.

11. The Radiation Safety Officer for this license is David E. Meimer.

12. Licensed material is only authorized for use by, or under the supervision of:

    A. Individuals permitted to work as an authorized medical physicist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

    B. The following individuals are authorized users for medical use as indicated:

Authorized User	Material and Use
Kishore Rao, M.D.	35.100; 35.200; 35.300; 31.11
William W. Ritchie, M.D.	35.100; 35.200, 35.300 except iodine-131 in quantities greater than 33 millicuries; 31.11
Stephen Adam Fink, M.D.	35.100; 35.200; 31.11
Stephen M. Hall, M.D.	35.100; 35.200; 31.11
Kevin Keith Wolsard, M.D.	35.100; 35.200; 35.300; 31.11
Stephen Dell Foxx, M.D.	35.100; 35.200; 31.11

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No.
35-09087-01

Docket No.
030-03331

Amendment No.
37

Authorized User	Material and Use
Christopher C. Sinesi, M.D.	35.300; 35.400
Mark S. Sinesi, M.D.	35.300; 35.400
Ravi V. Shamaiengar, M.D.	35.100; 35.200
Scott Seth Williams, M.D.	35.300; 35.400
Adedamola Omogbehin, M.D.	35.300; 35.400
Kelley Z. Allison, M.D.	35.100; 35.200
Michael S. Montileone, M.D.	35.100; 35.200
Bennie A. Skinner, M.D.	35.100; 35.200

C. The following individuals are authorized for medical uses as indicated:

User	Material and Use
David E. Weimer	For medical human use of licensed materials

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

15. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U. S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license.

16. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No.
13-09087-01

Docket No.
030-03331

Amendment No.
37

17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated March 31, 2004 [renewal w/ 3/30/04 cover letter]
    B. Letter dated May 25, 2004 [add users (Drs. Allison, Montileone and Skinner)]

For the U. S. Nuclear Regulatory Commission

Date September 10, 2004

By *Original signed by Bryan Parker*

Bryan Parker
Nuclear Materials Safety Branch 3
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406

Kendall L. Capecci, M.D.

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. **44**

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated **August 23, 2002**
1. Southside Regional Medical Center	3. License No. 45-00317-02 is amended in its entirety to read as follows:
2. 801 South Adams Street Petersburg, Virginia 23803	4. Expiration Date: October 31, 2005
	5. Docket No. 030-03301

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100 [redacted]	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200, except xenon gas	B. As needed
C. (1) Iodine 131	C. (1) Any capsule form for administration as specified in 10 CFR 35.300	C. (1) 55.5 gigabecquerels (1.5 curies)
(2) Any byproduct material with a half-life less than 120 days, except iodine 131	(2) Any form identified in 10 CFR 35.300 and initially distributed pursuant to 10 CFR Part 32 or an equivalent Agreement State regulation	(2) As needed
D. Any byproduct material identified in 10 CFR 35.500	D. Any diagnostic sealed source identified in 10 CFR 35.500 and registered pursuant to 10 CFR 32.210 or an equivalent Agreement State regulation	D. As needed (See item 9.D)
E. Any byproduct material identified in 10 CFR 31.11	E. Prepackaged Kits	E. As needed

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No.
45-00317-02

Docket No.
030-03301

Amendment No.
44

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
F. Americium 241	F. Sealed source (Amersham Model No. AMC. 24)	F. 518 megabecquerels (14 millicuries)

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.
B. Medical use described in 10 CFR 35.200.
C. Any radiopharmaceutical therapy approved in §35.300.
D. Sealed source contained in a compatible device (registered pursuant to 10 CFR 32.210 or an equivalent Agreement State regulation) for medical use identified in 10 CFR 35.500. The licensee may also possess one additional source plus shipping container for use incident to source exchange.
E. In vitro studies.
F. To be used in Seattle Analytic Model SS-10244 Anatomical Marker.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities at Southside Regional Medical Center, 801 South Adams Street, Petersburg, Virginia.

11. The Radiation Safety Officer for this license is **David M. Cohen, M.D.**

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users	Material and Use
A. Phillip H. McClure, M.D.	Medical use described in 10 CFR 31.11, 35.100, 35.200, 35.500, Phosphorus 32 as soluble phosphate for treatment of polycythemia vera, leukemia and bone metastases, and Americium 241 anatomical marker.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No.
45-00317-02

Docket No.
030-03301

Amendment No.
44

12. B. John Grizzard, M.D. — Medical use described in 10 CFR 31.11, 35.100, 35.200, 35.500, Iodine 131 as sodium iodide for treatment of hyperthyroidism, and Americium 241 anatomical marker.

    C. Elizabeth A. Dawson, M.D. — Medical use described in 10 CFR 31.11, 35.100, 35.200, 35.300, 35.500, and Americium 241 anatomical marker.

    D. David M. Cohen, M.D. — Medical use described in 10 CFR 31.11, 35.100, 35.200, 35.500, and Americium 241 anatomical marker.

    E. Cary Straton, M.D. — Medical use described in 10 CFR 31.11, 35.100, 35.200, 35.500 and Americium 241 anatomical marker.

    F. Kendall Capecci, M.D. — Medical use described in 10 CFR 31.11, 35.100, 35.200, 35.300, 35.500 and Americium 241 anatomical marker.

    G. Jeffrey Todd Morgan, M.D. — Medical use described in 10 CFR 35.100 and 35.200.

    H. Uma R. Prasad, M.D. — Medical use described in 10 CFR 31.11, 35.100, and 35.200.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.

14. Sealed sources containing licensed material shall not be opened by the licensee.

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application with letter dated June 23, 1995 (corrected to read 1995 instead of 1994)

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No.
45-00317-02

Docket No.
030-03301

Amendment No.
44

15. B. Letters dated:

1) September 27, 1995 [additional information about radiation safety program]
2) April 2, 1998 [temporary location of hot lab]
3) October 14, 1999 [request to add an Authorized User (J. Morgan)]
4) September 22, 2000 [remove Dr. Hyre, add Dr. Prasad as authorized user]
5) November 17, 2000 [fax with additional information to support Dr. Prasad's recentness of training and experience; and clarify Dr. Prasad's requested authorized use]
5) December 12, 2000 [fax with additional information about Dr. Prasad]
6) December 13, 2000 [fax with additional information about Dr. Prasad]
7) **August 23, 2002 [request to add new RSO; remove authorized user (A. Cohen)]**

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

DATE OCT 07 2002

BY Orysia Masnyk Bailey

Orysia Masnyk Bailey
Region II, Division of Nuclear Materials Safety
61 Forsyth Street, S.W., Suite 23T85
Atlanta, Georgia 30303

N:\ACTIVE\45-00317-02 A44.WPD

Virginia Commonwealth University

Environmental Health & Safety

Sanger Hall, B2-014
1101 East Marshall Street
P.O. Box 980112
Richmond, Virginia 23298-0112

804 828-6347
Fax: 804 828-1157
TDD: 1-800-828-1120
http://www.vcu.edu/oehs

June 18, 2002

To Whom it May Concern:

This is to verify that Andrew D. Lauve, M.D. was approved by the University's Radiation Safety Committee as an authorized user for manual and HDR brachytherapy (10 CFR 35.400 and 35.600), pursuant to the training and experience requirements in 10 CFR 35.940 and 35.960. The approval was based on a preceptor statement submitted by the supervising individual which included the following radionuclides and types of use: Pd-103 (prostate implants), I-125 (prostate implants), Cs-137 (gynecological uses), and Ir-192 (HDR brachytherapy). This approval was granted on September 11, 2003

Should you have any questions or need any additional information, please contact Mary Beth Taormina in our Radiation Safety section at (804) 828-7097.

Sincerely,

Dean W. Broga, Ph.D.
Director - Office of Environmental Health & Safety
Radiation Safety Officer

pc: Stanley Benedict, Ph.D.
VCUHS Radiation Oncology

This is to acknowledge the receipt of your letter/application dated

3/4/2005, and to inform you that the initial processing which includes an administrative review has been performed.

Amendment 45-16209-02

☒ There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

_____.

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 136673.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (RI)
(6-96)

Sincerely,
Licensing Assistance Team Leader

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02120
Status Code: 0
Fee Category: 7C
Exp. Date: 20141231
Fee Comments: CODE 23
Decom Fin Assur Reqd: N

LICENSE FEE TRANSMITTAL

A. REGION I

1. APPLICATION ATTACHED
   Applicant/Licensee: SENTARA WILLIAMSBURG COMMUNITY HOSP
   Received Date: 20050311
   Docket No: 3014703
   Control No.: 136673
   License No.: 45-16209-02
   Action Type: Amendment

2. FEE ATTACHED
   Amount: /
   Check No.: /

3. COMMENTS

Signed Rebecca Junod
Date 3/29/2005

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /__/)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for:
   Amendment _____
   Renewal _____
   License _____

3. OTHER _____
   _____

Signed _____
Date _____